Clinical pharmacology studies drug action and exposure in humans. It connects pharmacokinetics, physiological effects and evidence about benefit and harm. A mechanistic prediction and a measured clinical outcome require different kinds of evidence.
Assessment and management of the harmful effects of medicines in relation to their proposed use.
An astringent is a substance that produces a tightening or drying effect at a tissue surface, often through interactions with proteins. The historical category describes an observed local effect rather than one chemically uniform drug class.
Immunotherapy modifies or uses immune responses to affect disease. Strategies can enhance a response, suppress it or direct it toward a particular target. The umbrella term therefore does not mean that every treatment simply increases immunity.
A proton pump inhibitor suppresses gastric acid secretion by inhibiting the gastric proton-potassium transport system. Targeting the final secretory machinery differs from neutralizing acid already present in the stomach.
A nonsteroidal anti-inflammatory drug is a drug in the group including ibuprofen, naproxen and aspirin. These agents commonly reduce prostaglandin production through cyclooxygenase inhibition. Their shared pathway does not make their duration, selectivity or other effects identical.
Ibuprofen is a nonsteroidal anti-inflammatory drug acting through cyclooxygenase inhibition. It illustrates how one pathway can influence pain, fever and inflammation while also participating in normal tissue functions.
Naproxen is a nonsteroidal anti-inflammatory drug that reduces prostaglandin synthesis through cyclooxygenase inhibition. Its pharmacological class describes a shared mechanism, while its exposure time course is a separate pharmacokinetics question.
Aspirin is acetylsalicylic acid, a nonsteroidal anti-inflammatory drug that acetylates cyclooxygenase. Its persistent effect on platelet function illustrates the distinction between a drug’s presence in blood and the lifetime of its effect on a cellular target.
An antiemetic reduces or prevents vomiting. Different drugs act on different sensory and central pathways contributing to the response. A common clinical effect does not establish a single shared receptor mechanism.
An antifungal drug inhibits fungal growth or damages fungal cells. Different classes act on membrane sterols, cell-wall synthesis or cell division. The target helps explain both the range of susceptible organisms and limits of selectivity.[ref]
Clinical Treatment of Fungal Diseases: Antifungals by CDC. antifungal classes table
Fluconazole is an azole antifungal drug that interferes with fungal sterol synthesis. Changes in the target enzyme or access to the target can contribute to resistance. A susceptible species name therefore does not guarantee susceptibility of every isolate.[ref]
Nystatin is a polyene antifungal drug that disrupts fungal membranes. Its action differs from inhibition of cell-wall synthesis, illustrating how drugs against the same organism can attack different cellular structures.[ref]
Terbinafine is an antifungal drug inhibiting squalene epoxidase. Interference with sterol metabolism changes the fungal membrane system and promotes accumulation of precursor material.[ref]
Griseofulvin is an antifungal drug that interferes with the microtubular machinery needed for mitosis. This cellular action distinguishes it from antifungals directed principally at membrane sterols.[ref]
Ketoconazole is an azole antifungal drug affecting sterol synthesis. Formulation and route of administration are important parts of describing its use; a topical preparation and a systemic exposure are different pharmacological situations.
Articles by others on the same topic
There are currently no matching articles.